Letter to the Editor
Early clinical experience with imatinib in COVID-19: Searching for a dual effect

https://doi.org/10.1016/j.jinf.2021.02.002Get rights and content

Highlights

  • •

    Imatinib has shown antiviral and immunomodulatory properties in preclinical models.

  • •

    Imatinib could potentially be helpful in COVID-19.

  • •

    This is the first case series of COVID-19 patients treated with imatinib.

  • •

    Imatinib is a well-known drug whose safety profile seems acceptable in COVID-19.

Cited by (0)

View Abstract
© 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.